Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Phase 1 Recruiting 36 enrolled Telix Pharmaceuticals (Innovations) Pty Limited Merck KGaA, Darmstadt, Germany · collab

NaSequentialOpen-labelTreatment

Summary

This is an open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumors.

Timeline

Start: 2023-05-23
Primary completion: 2024-12
Completion: 2026-12

Publications

Johnstone CN, Osellame LD, Cao Z, McDonald AF, Rigopoulos A, Burvenich IJG, Wichmann CW, Guo N, Ivashkevich AN, Wheatcroft MP, Yan EB, Zimmermann A, Zenke FT, Sirrenberg C, Scott FE, Scott AM. DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma. J Nucl Med. 2025 Mar 3;66(3):385-390. doi: 10.2967/jnumed.124.268695.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	177Lu-TLX250	Unknown	10 mg	Intravenous
Subject	177Lu-TLX250	Unknown	1887 mbq	Intravenous
Subject	177Lu-TLX250	Unknown	2516 mbq	Intravenous
Subject	177Lu-TLX250	Unknown	3145 mbq	Intravenous
Subject	NEDISERTIB	Small molecule	100 mg	Oral
Subject	NEDISERTIB	Small molecule	150 mg	Oral
Subject	NEDISERTIB	Small molecule	200 mg	Oral

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Summary

Timeline

Publications

Drugs

Indications